Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cabergoline

FDA-approved product (tablet, oral), marketed as Cabergoline, Dostinex.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Cabergoline
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hypothalamic neoplasm
  • Parkinson disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prolactine inhibitors; Dopamine agonists
FDA pharmacologic class
Ergot Derivative FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cabergoline in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cabergoline with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Assess the Safety, Tolerability and Pharmacokinetics of Viaca (Sildenafil + Cabergoline) Compared With Sildenafil and Cabergoline

    NCT07732387 · start 2026-08-01

    Registered record
    Registry ID
    NCT07732387
    Conditions
    Erectile Dysfunctions; Healthy Volunteer
    Interventions
    Viaca; Sildenafil 50 mg; Cabergoline 0.5 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2026-09-19
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunctions; Healthy Volunteer
    InterventionViaca; Sildenafil 50 mg; Cabergoline 0.5 MG
    PhasePhase 1
    Registry statusNot yet recruiting

  • Carbergoline for Antipsychotic Induced Hyperprolactinemia.

    NCT07386080 · start 2026-05-01

    Registered record
    Registry ID
    NCT07386080
    Conditions
    Scizophrenia
    Interventions
    Cabergoline (Dopamine Agonist); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-05-01
    Completion
    2029-05-01
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionScizophrenia
    InterventionCabergoline (Dopamine Agonist); Placebo
    PhasePhase 4
    Registry statusNot yet recruiting

  • Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

    NCT07568574 · start 2026-03-12

    Registered record
    Registry ID
    NCT07568574
    Conditions
    Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
    Interventions
    Testosterone Enanthate; Testosterone Cypionate; Testosterone Propionate; Sustanon (testosterone); Testosterone Gel; Methenolone Enanthate (Primobolan); Nandrolone Decanoate (Deca-Durabolin); Estradiol Patch; Estradiol Capsule; Progesterone Cream; Progesterone Capsule; Human Growth Hormone (hGH); EPO Darbepoetin (Aranesp); Meldonium; Modafinil; Mixed amphetamine salts (Adderall); Clomiphene; Anastrozole; Levothyroxine; Liothyronine; hCG; hMG; Atorvastatin; Rosuvastatin; Bisoprolol; Nebivolol; Metoprolol; Propranolol; Lisinopril; Enalapril; Furosemide; Chlorothiazide; Cabergoline; Metformin; Basal Insulin Glargine (long-acting); Telmisartan; Losartan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2026-03-12
    Completion
    2033-03-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
    InterventionTestosterone Enanthate; Testosterone Cypionate; Testosterone Propionate; Sustanon (testosterone) +33 more
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • Safety and Potency of a High Cabergoline Dosage in Microprolactinomas

    NCT07463235 · start 2026-03-04

    Registered record
    Registry ID
    NCT07463235
    Conditions
    Prolactinoma; Prolactin Excess
    Interventions
    Cabergoline; Cabergoline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-03-04
    Completion
    2029-12-20
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProlactinoma; Prolactin Excess
    InterventionCabergoline; Cabergoline
    PhasePhase 3
    Registry statusRecruiting

  • Cabergoline for Episodic Migraine

    NCT07072910 · start 2025-11-12

    Registered record
    Registry ID
    NCT07072910
    Conditions
    Migraine
    Interventions
    Cabergoline 0.5 MG; Placebo; Cabergoline 1 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-11-12
    Completion
    2028-09-01
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionCabergoline 0.5 MG; Placebo; Cabergoline 1 MG
    PhasePhase 2
    Registry statusRecruiting

  • A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets

    NCT07124221 · start 2025-09-12

    Registered record
    Registry ID
    NCT07124221
    Conditions
    Hyperprolactinemia
    Interventions
    Cabergoline tablets; Bromocriptine mesylate tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-09-12
    Completion
    2026-12-30
    Enrolment
    382

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperprolactinemia
    InterventionCabergoline tablets; Bromocriptine mesylate tablets
    PhasePhase 3
    Registry statusRecruiting

  • A Study on Bioequivalence of Cabergoline Tablets in Human Body

    NCT07008417 · start 2025-06-30

    Registered record
    Registry ID
    NCT07008417
    Conditions
    Hyperprolactinemia
    Interventions
    Cabergoline tablets test formulation; Cabergoline tablets reference formulation
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2025-06-30
    Completion
    2026-05-06
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperprolactinemia
    InterventionCabergoline tablets test formulation; Cabergoline tablets reference formulation
    PhasePhase 1
    Registry statusActive not recruiting

  • Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS

    NCT07255911 · start 2025-02-07

    Registered record
    Registry ID
    NCT07255911
    Conditions
    PCOS
    Interventions
    Letrozole 0.5mg; Cabergoline 0.5 mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-02-07
    Completion
    2026-06-30
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPCOS
    InterventionLetrozole 0.5mg; Cabergoline 0.5 mg
    PhaseNot applicable
    Registry statusRecruiting

  • Cabergoline in the Management of Nonfunctioning Pituitary Adenoma

    NCT07034859 · start 2024-05-20

    Registered record
    Registry ID
    NCT07034859
    Conditions
    Pituitary Adenoma; MRI; RCT
    Interventions
    Cabergoline 0.5 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Enrolling by invitation
    Start
    2024-05-20
    Completion
    2028-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPituitary Adenoma; MRI; RCT
    InterventionCabergoline 0.5 MG
    PhasePhase 4
    Registry statusEnrolling by invitation

  • Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction

    NCT07168837 · start 2023-01-10

    Registered record
    Registry ID
    NCT07168837
    Conditions
    PCOS (Polycystic Ovary Syndrome)
    Interventions
    Letrozole tablets
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-01-10
    Completion
    2024-05-10
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPCOS (Polycystic Ovary Syndrome)
    InterventionLetrozole tablets
    PhaseNot applicable
    Registry statusCompleted

  • Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin

    NCT06333691 · start 2022-10-01

    Registered record
    Registry ID
    NCT06333691
    Conditions
    Ovarian Hyperstimulation Syndrome
    Interventions
    Calcium Gluconate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-10-01
    Completion
    2024-02-15
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Hyperstimulation Syndrome
    InterventionCalcium Gluconate
    PhaseNot applicable
    Registry statusCompleted

  • Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS

    NCT05981742 · start 2022-09-21

    Registered record
    Registry ID
    NCT05981742
    Conditions
    Polycystic Ovary Syndrome
    Interventions
    Metformin Hydrochloride 500 MG; Cabergoline 0.5 MG; Metformin Hydrochloride 500 MG + Cabergoline 0.5 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-09-21
    Completion
    2023-03-31
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome
    InterventionMetformin Hydrochloride 500 MG; Cabergoline 0.5 MG; Metformin Hydrochloride 500 MG + Cabergoline 0.5 MG
    PhasePhase 2
    Registry statusCompleted

  • Cabergoline as a Preventive Treatment for Chronic Migraine

    NCT05525611 · start 2022-09-05

    Registered record
    Registry ID
    NCT05525611
    Conditions
    Migraine
    Interventions
    Cabergoline 0.5 MG; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-09-05
    Completion
    2023-08-08
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionCabergoline 0.5 MG; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Non-surgical Interventions for Infertility in Endometriosis

    NCT06560814 · start 2020-07-01

    Registered record
    Registry ID
    NCT06560814
    Conditions
    Endometriosis; Infertility, Female
    Interventions
    Cabergoline plus timed intercourse; Dydrogesterone plus timed intercourse
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-07-01
    Completion
    2021-06-30
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis; Infertility, Female
    InterventionCabergoline plus timed intercourse; Dydrogesterone plus timed intercourse
    PhasePhase 2
    Registry statusCompleted

  • Clinical Guidance for Proper Treatment of Unexplained Resistant Hyperprolactinemia.

    NCT04262024 · start 2020-02-01

    Registered record
    Registry ID
    NCT04262024
    Conditions
    Health Education
    Interventions
    cabergoline 1.5-2 mg/week).orally daily for 1 month plus health education; cabergoline 1.5-2 mg/week).orally daily for 1 month without health education
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-02-01
    Completion
    2023-05-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealth Education
    Interventioncabergoline 1.5-2 mg/week).orally daily for 1 month plus health education; cabergoline 1.5-2 mg/week).orally daily for 1 month without health education
    PhasePhase 1
    Registry statusCompleted